Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Coronavirus Notebook: EU Moots Emergency Use Authorization Scheme For Vaccines, Janssen Product Up For 11 March Approval

Executive Summary

Celltrion’s regdanvimab is undergoing an emergency use procedure in Europe, the European Medicines Agency and the health authorities in Canada have jointly published clinical data on the Moderna vaccine, and Canada has approved two versions of the AstraZeneca/Oxford University jab.

You may also be interested in...



Pivotal Moment In EU For Potential New Drugs

Decisions are due on several EU marketing applications at the March meeting of the European Medicines Agency’s drug evaluation committee, the CHMP. Also, a number of companies might be asked to address outstanding issues the CHMP has about products they want to market that are near the final stages of review.

Coronavirus Notebook: AZ Vaccine Suspended In Some European Countries, Janssen’s Vaccine Approved In EU

The European Commission has ordered more doses of the Pfizer/BioNTech vaccine to tackle COVID-19 “hotspots,” and has extended its export authorization scheme by three months. The EU’s procurement strategy has come under fire again, Lilly's antibodies have started a rolling review at the European Medicines Agency, and Sierra Leone has received its first coronavirus vaccines via the COVAX Facility.

Slovakia Becomes Second EU Country To OK Use Of Russian Vaccine

While the EU attempts to accelerate the pace of its unified approach to vaccine roll-out, some eastern European countries are taking their own decisions.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS143880

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel